Sigilon Therapeutics, Inc.
SGTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 34.8% | -28.2% | -5.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -300.3% | -781.4% | -397.7% | -299.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -335.7% | -815% | -410.3% | -314.9% |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 |
| % Growth | 95.8% | -40.8% | 17.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |